Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson’s disease

OBJECTIVE: To identify determinants for the discontinuation of non-ergoline dopamine agonist (DA) treatment in patients with Parkinson’s disease (PD) and to identify genetic determinants in genes encoding dopamine receptor (DR)D2 and DRD3 in a exploratory analysis. METHODS: Patients included were fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Arbouw, Maurits E. L., Movig, Kris L. L., Egberts, Toine C. G., Poels, Petra J. E., van Vugt, Jeroen P. P., Wessels, Judith A. M., van der Straaten, R. J. H. M., Neef, Cees, Guchelaar, Henk-Jan
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2009
Materias:
Pharmacoepidemiology and Prescription
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778789/
https://www.ncbi.nlm.nih.gov/pubmed/19669131
http://dx.doi.org/10.1007/s00228-009-0708-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778789/
https://www.ncbi.nlm.nih.gov/pubmed/19669131
http://dx.doi.org/10.1007/s00228-009-0708-6

Ejemplares similares